Evidence map›Paper›PMID 35069106›Full record

ArticleFrontiers in neuroscience2021

Aline Freyssin, Agnès Rioux Bilan, Bernard Fauconneau, Laurent Galineau, Sophie Serrière, Clovis Tauber, Flavie Perrin, Jérôme Guillard, Sylvie Chalon, Guylène Page

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. ε-Viniferin Rejuvenates Senescence viaPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
  4. WildMolecules (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Aline FreyssinEA3808 Neurovascular Unit and Cognitive Disorders, University of Poitiers, Poitiers, France.
Agnès Rioux BilanEA3808 Neurovascular Unit and Cognitive Disorders, University of Poitiers, Poitiers, France.
Bernard FauconneauEA3808 Neurovascular Unit and Cognitive Disorders, University of Poitiers, Poitiers, France.
Laurent GalineauUMR 1253, iBrain, Inserm, Faculty of Medicine, Université de Tours, Tours, France.
Sophie SerrièreUMR 1253, iBrain, Inserm, Faculty of Medicine, Université de Tours, Tours, France.
Clovis TauberUMR 1253, iBrain, Inserm, Faculty of Medicine, Université de Tours, Tours, France.
Flavie PerrinUMR CNRS 7285 IC2MP, Team 5 Organic Synthesis, University of Poitiers, Poitiers, France.
Jérôme GuillardUMR CNRS 7285 IC2MP, Team 5 Organic Synthesis, University of Poitiers, Poitiers, France.
Sylvie ChalonUMR 1253, iBrain, Inserm, Faculty of Medicine, Université de Tours, Tours, France.
Guylène PageEA3808 Neurovascular Unit and Cognitive Disorders, University of Poitiers, Poitiers, France.
Université de Poitiers · FRInserm · FRInstitut de Chimie des Milieux et des Matériaux de Poitiers · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a previous study, we showed that viniferin decreased amyloid deposits and reduced neuroinflammation in APPswePS1dE9 transgenic mice between 3 and 6 months of age. In the present study, wild type and APPswePS1dE9 transgenic mice were treated from 7 to 11 or from 3 to 12 months by a weekly intraperitoneal injection of either 20 mg/kg viniferin or resveratrol or their vehicle, the polyethylene glycol 200 (PEG 200). The cognitive status of the mice was evaluated by the Morris water maze test. Then, amyloid burden and neuroinflammation were quantified by western-blot, Enzyme-Linked ImmunoSorbent Assay (ELISA), immunofluorescence, and

Indexed as

Alzheimer’s diseaseamyloid depositsmemory declinePET imagingresveratrolviniferin

Identifiers

PMID35069106
PMCPMC8770934
OpenAlexW4206770353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.